SEARCH

SEARCH BY CITATION

References

  • Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th Edition. Br J Pharmacol 158 (Suppl.1): S1S254.
  • Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z et al. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353: 2331.
  • Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L et al. (2001). Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 15: 27452747.
  • Bifulco M, Malfitano AM, Pisanti S, Laezza C (2008). Endocannabinoids in endocrine and related tumours. Endocr Relat Cancer 15: 391408.
  • Bíró T, Tóth BI, Haskó G, Paus R, Pacher P (2009). The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci 30: 411420.
  • Bisogno T, Katayama K, Melck D, Ueda N, De Petrocellis L, Yamamoto S et al. (1998). Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells – implications for cell proliferation and differentiation. Eur J Biochem 254: 634642.
  • Blazquez C, Casanova ML, Planas A, Gomez Del Pulgar T, Villanueva C, Fernandez-Acenero MJ et al. (2003). Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17: 529531.
  • Bovée JV, Hogendoorn PC, Wunder JS, Alman BA (2010). Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 10: 481488.
  • Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A (2010). Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 46: 30403052.
  • Brown I, Cascio MG, Wahle KW, Smoum R, Mechoulam R, Ross RA et al. (2010). Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis 31: 15841591.
  • Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC et al. (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. Eur J Pharmacol 396: 141149.
  • von Bueren AO, Schlumpf M, Lichtensteiger W (2008). Delta(9)-tetrahydrocannabinol inhibits 17beta-estradiol-induced proliferation and fails to activate androgen and estrogen receptors in MCF7 human breast cancer cells. Anticancer Res 28: 8589.
  • Burstein S, Salmonsen R (2008). Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation. Bioorg Med Chem 16: 96449651.
  • Caffarel MM, Sarrió D, Palacios J, Guzmán M, Sánchez C (2006). Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 66: 66156621.
  • Caffarel MM, Moreno-Bueno G, Cerutti C, Palacios J, Guzman M, Mechta-Grigoriou F et al. (2008). JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene 27: 50335044.
  • Caffarel MM, Andradas C, Mira E, Pérez-Gómez E, Cerutti C, Moreno-Bueno G et al. (2010). Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer 9: 196206.
  • Carchman RA, Harris LS, Munson AE (1976). The inhibition of DNA synthesis by cannabinoids. Cancer Res 36: 95100.
  • Chung SC, Hammarsten P, Josefsson A, Stattin P, Granfors T, Egevad L et al. (2009). A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer 45: 174182.
  • Curto-Reyes V, Llames S, Hidalgo A, Menéndez L, Baamonde A (2010). Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain. Br J Pharmacol 160: 561573.
  • Czifra G, Varga A, Nyeste K, Marincsák R, Tóth BI, Kovács I et al. (2009). Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. J Cancer Res Clin Oncol 135: 507514.
  • Davis MP (2008). Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs 17: 8595.
  • De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M et al. (1998). The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 95: 83758380.
  • De Petrocellis L, Bisogno T, Ligresti A, Bifulco M, Melck D, Di Marzo V (2002). Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam Clin Pharmacol 16: 297302.
  • Di Marzo V (2006). Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 160: 124.
  • Di Marzo V (2008). Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7: 438455.
  • Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M et al. (2001). Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 358: 249255.
  • Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B et al. (2010). Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 341: 45434551.
  • Doré-Savard L, Otis V, Belleville K, Lemire M, Archambault M, Tremblay L et al. (2010). Behavioral, medical imaging and histopathological features of a new rat model of bone cancer pain. Plos One 5: 1377413788.
  • Endsley MP, Aggarwal N, Isbell MA, Wheelock CE, Hammock BD, Falck JR et al. (2007). Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12-lipoxygenase metabolism. Int J Cancer 121: 984991.
  • Endsley MP, Thill R, Choudhry I, Williams CL, Kajdacsy-Balla A, Campbell WB et al. (2008). Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer 123: 13181326.
  • Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 28932917.
  • Fontanini G (2000). Angiogenesis and cancer. Surg Technol Int 9: 2532.
  • Ford LA, Roelofs AJ, Anavi-Goffer S, Mowat L, Simpson DG, Irving AJ et al. (2010). A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 160: 762771.
  • Furuse S, Kawamata T, Yamamoto J, Niiyama Y, Omote K, Watanabe M et al. (2009). Reduction of bone cancer pain by activation of spinal cannabinoid receptor 1 and its expression in the superficial dorsal horn of the spinal cord in a murine model of bone cancer pain. Anesthesiology 111: 173186.
  • Glass AG, Lacey JV Jr, Carreon JD, Hoover RN (2007). Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99: 11521161.
  • Gómez del Pulgar T, Velasco G, Guzmán M (2000). The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 347: 369373.
  • Grimaldi C, Pisanti S, Laezza C, Malfitano AM, Santoro A, Vitale M et al. (2006). Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 312: 363373.
  • Guindon J, Hohmann AG (2009). The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 8: 403421.
  • Guise TA, Brufsky A, Coleman RE (2010). Understanding and optimizing bone health in breast cancer. Curr Med Res Opin 26: 320.
  • Guzmán M (2003). Cannabinoids: potential anticancer agents. Nat Rev Cancer 3: 745755.
  • Hald A, Ding M, Egerod K, Hansen RR, Konradsen D, Jørgensen SG et al. (2008). Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55,212-2 in experimental models of bone cancer pain and neuropathic pain. Pharmacol Biochem Behav 91: 3846.
  • Hamamoto DT, Giridharagopalan S, Simone DA (2007). Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia. Eur J Pharmacol 558: 7387.
  • Hancox RJ, Poulton R, Ely M, Welch D, Taylor DR, McLachlan CR et al. (2010). Effects of cannabis on lung function: a population-based cohort study. Eur Respir J 35: 4247.
  • Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B (2009). Deaths: final data for 2006. National Vital Statistics Reports 57: 1135.
  • Jhaveri MD, Richardson D, Chapman V (2007). Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 152: 624632.
  • Jimenez-Andrade JM, Bloom AP, Stake JI, Mantyh WG, Taylor RN, Freeman KT et al. (2010a). Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. J Neurosci 30: 1464914656.
  • Jimenez-Andrade JM, Mantyh WG, Bloom AP, Ferng AS, Geffre CP, Mantyh PW (2010b). Bone cancer pain. Ann N Y Acad Sci 1198: 173181.
  • Jochimsen PR, Lawton RL, VerSteeg K, Noyes R (1978). Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clin Pharmacol Ther 24: 223227.
  • Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT (2010). Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39: 167179.
  • Khasabova IA, Khasabov SG, Harding-Rose C, Coicou LG, Seybold BA, Lindberg AE et al. (2008). A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J Neurosci 28: 1114111152.
  • Kogan NM (2005). Cannabinoids and Cancer. Mini Rev Med Chem 5: 941952.
  • Laezza C, Pisanti S, Malfitano AM, Bifulco M (2008). The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway. Endocr Relat Cancer 15: 965974.
  • Laezza C, Malfitano AM, Proto MC, Esposito I, Gazzerro P, Formisano P et al. (2010). Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells. Endocr Relat Cancer 17: 495503.
  • Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F et al. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiate in CB1 receptor knockout mice. Science 283: 401404.
  • Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L et al. (2006). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318: 13751387.
  • Lozano-Ondoua AN, Wright C, Vardanyan A, King T, Largent-Milnes TM, Nelson M et al. (2010). A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Life Sci 86: 646653.
  • McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY (2007). Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 6: 29212927.
  • McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J et al. (2010). Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat DOI: 10.1007/S10549-010-1177-4. PMID: 20859676.
  • McKallip RJ, Nagarkatti M, Nagarkatti PS (2005). Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol 174: 32813289.
  • Maccarrone M, Lorenzon T, Bari M, Melino G, Finazzi-Agro A (2000). Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem 275: 3193831945.
  • Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN (1995). Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 87: 16811685.
  • Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561564.
  • Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzmán M, Di Marzo V (1999). Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 463: 235240.
  • Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M et al. (2000). Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141: 118126.
  • Mercadante S (1997). Malignant bone pain: pathophysiology and treatment. Pain 69: 118.
  • Mimeault M, Pommery N, Wattez N, Bailly C, Hénichart JP (2003). Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56: 112.
  • Movsesyan VA, Stoica BA, Yakovlev AG, Knoblach SM, Lea PM 4th, Cernak I et al. (2004). Anandamide-induced cell death in primary neuronal cultures: role of calpain and caspase pathways. Cell Death Differ 11: 11211132.
  • Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 6165.
  • Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA (1975). Antineoplastic activity of cannabinoids. J Natl Cancer Inst 55: 597602.
  • Navari RM (2009). Antiemetic control: toward a new standard of care for ematogenic chemotherapy. Expert Opin Pharmacother 10: 629644.
  • Nithipatikom K, Endsley MP, Isbell MA, Falck JR, Iwamoto Y, Hillard CJ et al. (2004). 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res 64: 88268830.
  • Nithipatikom K, Endsley MP, Isbell MA, Wheelock CE, Hammock BD, Campbell WB (2005). A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. Biochem Biophys Res Commun 332: 10281033.
  • Noyes R, Brunk SF, Baram DA, Canter A (1975a). Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 15: 139143.
  • Noyes R, Brunk SF, Avery DA, Canter AC (1975b). The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 18: 8489.
  • Olea-Herrero N, Vara D, Malagarie-Cazenave S, Díaz-Laviada I (2009a). Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2. Br J Cancer 101: 940950.
  • Olea-Herrero N, Vara D, Malagarie-Cazenave S, Díaz-Laviada I (2009b). The cannabinoid R+ methanandamide induces IL-6 secretion by prostate cancer PC3 cells. J Immunotoxicol 6: 249256.
  • Pacher P, Mechoulam R (2011). Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 50: 193211.
  • Pacher P, Batkai S, Kunos G (2006). The endocannabioid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389462.
  • Pantel K, Alix-Panabières C (2010). Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 16: 398406.
  • Parker LA, Rock E, Limebeer C (2011). Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol 163: 14111422.
  • Parkin D, Bray F, Devesa S (2001). Cancer burden in the year 2000. The global picture. Eur J Cancer 37: S4S66.
  • Piñeiro R, Maffucci T, Falasca M (2011). The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 30: 142152.
  • Piomelli D (2005). The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 6: 672679.
  • Portenoy RK, Payne D, Jacobsen P (1999). Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81: 129134.
  • Potenzieri C, Harding-Rose C, Simone DA (2008). The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Res 1215: 6975.
  • Qamri Z, Preet A, Nasser MW, Bass CE, Leone G, Barsky SH et al. (2009). Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther 8: 31173129.
  • Rahn EJ, Hohmann AG (2009). Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics 6: 713737.
  • Ribatti D, Crivellato E (2010). Mast cells, angiogenesis and tumour growth. Biochim Biophys Acta DOI: 10.1016/j.bbadi3.2010.11.010. PMID: 21130163.
  • Ruh MF, Taylor JA, Howlett AC, Welshons WV (1997). Failure of cannabinoid compounds to stimulate estrogen receptors. Biochem Pharmacol 53: 3541.
  • Ruiz L, Miguel A, Díaz-Laviada I (1999). Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett 458: 400404.
  • Ruiz-Llorente L, Ortega-Gutiérrez S, Viso A, Sánchez MG, Sánchez AM, Fernández C et al. (2004). Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study. Br J Pharmacol 141: 457467.
  • Sánchez MG, Ruiz-Llorente L, Sánchez AM, Díaz-Laviada I (2003a). Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal 15: 851859.
  • Sánchez MG, Sánchez AM, Ruiz-Llorente L, Díaz-Laviada I (2003b). Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. FEBS Lett 555: 561566.
  • Sarfaraz S, Afaq F, Adhami VM, Mukhtar H (2005). Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 65: 16351641.
  • Sarfaraz S, Afaq F, Adhami VM, Malik A, Mukhtar H (2006). Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem 281: 3948039491.
  • Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H (2008). Cannabinoids for cancer treatment: progress and promise. Cancer Res 68: 339342.
  • Sarnataro D, Grimaldi C, Pisanti S, Gazzerro P, Laezza C, Zurzolo C et al. (2005). Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. FEBS Lett 579: 63436349.
  • Sarnataro D, Pisanti S, Santoro A, Gazzerro P, Malfitano AM, Laezza C et al. (2006). The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol 70: 12981306.
  • Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. (2009). Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 13201328.
  • Staquet M, Gantt C, Machin D (1978). Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 23: 397401.
  • Takeda S, Yamaori S, Motoya E, Matsunaga T, Kimura T, Yamamoto I et al. (2008). Delta(9)-Tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling. Toxicology 245: 141146.
  • Takeda S, Yamamoto I, Watanabe K (2009). Modulation of Delta9-tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase. Toxicology 259: 2532.
  • Tan WC, Lo C, Jong A, Xing L, Fitzgerald MJ, Vollmer WM et al. (2009). Marijuana and chronic obstructive lung disease: a population-based study. CMAJ 180: 814820.
  • Tashkin DP (2005). Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis 63: 93100.
  • Thors L, Bergh A, Persson E, Hammarsten P, Stattin P, Egevad L et al. (2010). Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. Plos One 5: 1227512286.
  • Velasco L, Ruiz L, Sánchez MG, Díaz-Laviada I (2001). Delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1. Eur J Biochem 268: 531535.
  • Velasco G, Carracedo A, Blázquez C, Lorente M, Aguado T, Haro A et al. (2007). Cannabinoids and gliomas. Mol Neurobiol 36: 6067.
  • Wang J, Ueda N (2009). Biology of the endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat 89: 112119.
  • Wang J, Zhao LY, Uyama T, Tsuboi K, Wu XX, Kakehi Y et al. (2008). Expression and secretion of N-acylethanolamine-hydrolysing acid amidase in human prostate cancer cells. J Biochem 144: 685690.
  • Watanabe K, Motoya E, Matsuzawa N, Funahashi T, Kimura T, Matsunaga T et al. (2005). Marijuana extracts possess the effects like the endocrine disrupting chemicals. Toxicology 206: 471478.
  • Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999). Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96: 57805785.